Human Insulin

FDA Drug Profile — Novolin R, Novolin N, Novolin 70/30

Human Insulin is listed in the FDA National Drug Code directory with 12 NDC codes, marketed under brand names including Novolin R, Novolin N, Novolin 70/30. Available dosage forms: injection, solution, injection, suspension.

Drug details

Generic Name
Human Insulin
Brand Names
Novolin R, Novolin N, Novolin 70/30
Application Number
BLA019938
Sponsor
Novo Nordisk
NDC Codes
12
Dosage Forms
INJECTION, SOLUTION, INJECTION, SUSPENSION
Routes
SUBCUTANEOUS
Active Ingredients
INSULIN HUMAN

Indications and Usage

1 INDICATIONS AND USAGE NOVOLIN 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. Limitations of Use: In NOVOLIN 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. NOVOLIN 70/30 is a mixture of human insulin isophane, an intermediate-acting human insulin, and human insulin, a short-acting human insulin, indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.